Prescription Drugs

CLINICAL PHARMACOLOGY Lamprene (clofazimine) exerts a slow bactericidal effect on Mycobacterium leprae (Hansen's bacillus). Lamprene (clofazimine) inhibits mycobacterial growth and binds preferentially to mycobacterial DNA. Lamprene (clofazimine) also exerts anti-inflammatory properties in controlling erythema nodosum leprosum reactions. However, its precise mechanisms of action are unknown. Pharmacokinetics Lamprene (clofazimine) has a variable absorption rate in leprosy patients, ranging from 45%-62% after oral administration. The average serum concentrations in leprosy patients treated with 100 mg and 300 mg daily were 0.7 µg/mL and 1.0 µg/mL, respectively. After ingestion of a single dose of 300 mg, elimination of unchanged Lamprene (clofazimine) and its metabolites in a 24-hour urine collection was negligible. Lamprene (clofazimine) is retained in the human body for a long time. The half-life of Lamprene (clofazimine) following repeated oral doses is estimated to be at least 70 days. Part of the ingested drug recovered from the feces may represent excretion via the bile. A small amount is also eliminated in the sputum, sebum, and sweat. Lamprene (clofazimine) is highly lipophilic and tends to be deposited predominantly in fatty tissue and in cells of the reticuloendothelial system. It is taken up by macrophages throughout the body. In autopsies performed on leprosy patients, clofazimine crystals were found predominantly in the mesenteric lymph nodes, adrenals, subcutaneous fat, liver, bile, gall bladder, spleen, small intestine, muscles, bones, and skin. Microbiology Measurement of the minimum inhibitory concentration (MIC) of Lamprene (clofazimine) against leprosy bacilli in vitro is not yet feasible. In the mouse footpad system, the multiplication of M. leprae is inhibited by introducing 0.0001%- 0.001% Lamprene (clofazimine) in the diet. Although bacterial killing may begin shortly after starting the drug, it cannot be measured in biopsy tissues taken from patients for mouse footpad studies until approximately 50 days after the start of therapy. Lamprene (clofazimine) does not show cross-resistance with dapsone or rifampin. The following in vitro data are available, but their clinical significance is unknown. Lamprene (clofazimine) has been shown in vitro to inhibit M. avium and M. bovis at concentrations of approximately 0.1-1.0 µg/mL. The MIC for M. avium-intracellulare isolated from patients with acquired immunodeficiency syndrome (AIDS) ranged from 1.0 to 5.0 µg/mL. With a few exceptions, microorganisms other than mycobacteria are not inhibited by Lamprene (clofazimine) .

Lamprene® (clofazimine) Soft Gelatin Capsules DESCRIPTION Lamprene, clofazimine, is an antileprosy agent available as soft gelatin capsules for oral administration. Each capsule contains 50 mg of micronized clofazimine suspended in an oil-wax base. Clofazimine is a substituted iminophenazine bright-red dye. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-isopropyliminophenazine, and its structural formula is Clofazimine is a reddish-brown powder. It is readily soluble in benzene; soluble in chloroform; poorly soluble in acetone and in ethyl acetate; sparingly soluble in methanol and in ethanol; and virtually insoluble in water. Its molecular weight is 473.4. Inactive Ingredients. Beeswax, butylated hydroxytoluene, citric acid, ethyl vanillin, gelatin, glycerin, iron oxide, lecithin, p-methoxy acetophenone, parabens, plant oils, propylene glycol.

INDICATIONS Lamprene (clofazimine) is indicated in the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum. Lamprene (clofazimine) has not been demonstrated to be effective in the treatment of other leprosy-associated inflammatory reactions. Combination drug therapy has been recommended for initial treatment of multibacillary leprosy to prevent the development of drug resistance. DOSAGE AND ADMINISTRATION Lamprene (clofazimine) should be taken with meals. Lamprene (clofazimine) should be used preferably in combination with one or more other antileprosy agents to prevent the emergence of drug resistance. For the treatment of proven dapsone-resistant leprosy, Lamprene (clofazimine) should be given at a dosage of 100 mg daily in combination with one or more other antileprosy drugs for 3 years, followed by monotherapy with 100 mg of Lamprene (clofazimine) daily. Clinical improvement usually can be detected between the first and third months of treatment and is usually clearly evident by the sixth month. For dapsone-sensitive multibacillary leprosy, a combination therapy with two other antileprosy drugs is recommended. The triple-drug regimen should be given for at least 2 years and continued, if possible, until negative skin smears are obtained. At this time, monotherapy with an appropriate antileprosy drug can be instituted. The treatment of erythema nodosum leprosum reactions depends on the severity of symptoms. In general, the basic antileprosy treatment should be continued, and if nerve injury or skin ulceration is threatened, corticosteroids should be given. Where prolonged corticosteroid therapy becomes necessary, Lamprene (clofazimine) administered at dosages of 100 to 200 mg daily for up to 3 months may be useful in eliminating or reducing corticosteroid requirements. Dosages above 200 mg daily are not recommended, and the dosage should be tapered to 100 mg daily as quickly as possible after the reactive episode is controlled. The patient must remain under medical surveillance. For advice about combination drug regimens, contact the USPHS Gillis W. Long Hansen's Disease Center, Carville, LA (504-642-7771). HOW SUPPLIED Soft Gelatin Capsules 50 mg–brown, spherical Bottles of 100...........................NDC 0028-0108-01 Store below 30ºC (86ºF). Protect from moisture. Dispense in tight container (USP). Distributed by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936. Rev 9/98. FDA rev date: 6/11/2003

PATIENT INFORMATION Patients should be warned that Lamprene (clofazimine) may cause a discoloration of the skin from red to brownish-black, as well as discoloration of the conjunctivae, lacrimal fluid, sweat, sputum, urine, and feces. Patients should be advised that skin discoloration, although reversible, may take several months or years to disappear after the conclusion of therapy with Lamprene (clofazimine) . Patients should be told to take Lamprene (clofazimine) with meals.

OVERDOSE No specific data are available on the treatment of overdosage with Lamprene (clofazimine) . However, in case of overdose, the stomach should be emptied by inducing vomiting or by gastric lavage, and supportive symptomatic treatment should be employed. CONTRAINDICATIONS There are no known contraindications.

SIDE EFFECTS In general, Lamprene (clofazimine) is well tolerated when administered in dosages no greater than 100 mg daily. The most consistent adverse reactions are usually dose related and are usually reversible when Lamprene (clofazimine) is discontinued. Adverse Reactions Occurring In More Than 1% of Patients Skin: Pigmentation from pink to brownish-black in 75%-100% of the patients within a few weeks of treatment; ichthyosis and dryness (8%-28%); rash and pruritus (1%-5%). Gastrointestinal: Abdominal and epigastric pain, diarrhea, nausea, vomiting, gastrointestinal intolerance (40%-50%). Ocular: Conjunctival and corneal pigmentation due to clofazimine crystal deposits; dryness; burning; itching; irritation. Other: Discoloration of urine, feces, sputum, sweat; elevated blood sugar; elevated ESR. Adverse Reactions Occurring In Less Than 1% of Patients Skin:Phototoxicity, erythroderma, acneiform eruptions, monilial cheilosis. Gastrointestinal:Bowel obstruction (see WARNINGS), gastrointestinal bleeding (see WARNINGS), anorexia, constipation, weight loss, hepatitis, jaundice, eosinophilic enteritis, enlarged liver. Ocular: Diminished vision. Nervous: Dizziness, drowsiness, fatigue, headache, giddiness, neuralgia, taste disorder. Psychiatric:Depression secondary to skin discoloration; two suicides have been reported. Laboratory: Elevated levels of albumin, serum bilirubin, and AST (SGOT); eosinophilia; hypokalemia. Other:Splenic infarction (see WARNINGS), thromboembolism, anemia, cystitis, bone pain, edema, fever, lymphadenopathy, vascular pain. DRUG INTERACTIONS Preliminary data which suggest that dapsone may inhibit the anti-inflammatory activity of Lamprene (clofazimine) have not been confirmed. If leprosy-associated inflammatory reactions develop in patients being treated with dapsone and clofazimine, it is still advisable to continue treatment with both drugs.

WARNINGS Severe abdominal symptoms (see below) have necessitated exploratory laparotomies in some patients receiving Lamprene (clofazimine) . Rare reports have included splenic infarction, bowel obstruction, and gastrointestinal bleeding. There have also been reports of death following severe abdominal symptoms. Autopsies have revealed crystalline deposits of clofazimine in various tissues including the intestinal mucosa, liver, spleen, and mesenteric lymph nodes. Lamprene (clofazimine) should be used with caution in patients who have gastrointestinal problems such as abdominal pain and diarrhea. Dosages of Lamprene (clofazimine) of more than 100 mg daily should be given for as short a period as possible and only under close medical supervision. If a patient complains of colicky or burning pain in the abdomen, nausea, vomiting, or diarrhea, the dose should be reduced, and if necessary, the interval between doses should be increased, or the drug should be discontinued. PRECAUTIONS General Physicians should be aware that skin discoloration due to Lamprene (clofazimine) may result in depression. Two suicides have been reported in patients receiving Lamprene (clofazimine) . For skin dryness and ichthyosis, oil can be applied to the skin. Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term carcinogenicity studies in animals have not been conducted with Lamprene (clofazimine) . Results of mutagenicity studies (Ames test) were negative. There was some evidence of impaired fertility in one study in rats treated at a dose 25 times the usual human dose; the number of offspring was reduced and there was a lower proportion of implantations. Pregnancy Category C Lamprene (clofazimine) was not teratogenic in laboratory animals at dose levels equivalent to 8 times (rabbit) and 25 times (rat) the usual human daily dose. However, there was evidence of fetotoxicity in the mouse at 12-25 times the human dose, i.e., retardation of fetal skull ossification, increased incidence of abortions and stillbirths, and impaired neonatal survival. The skin and fatty tissue of offspring became discolored approximately 3 days after birth, which was attributed to the presence of Lamprene (clofazimine) in the maternal milk. It has been found that Lamprene (clofazimine) crosses the human placenta. The skin of infants born to women who had received the drug during pregnancy was found to be deeply pigmented at birth. No evidence of teratogenicity was found in these infants. There are no adequate and well-controlled studies in pregnant women. Lamprene (clofazimine) should be used during pregnancy only if the potential benefit justifies the risk to the fetus. Nursing Mothers Lamprene (clofazimine) is excreted in the milk of nursing mothers. Lamprene (clofazimine) should not be administered to a nursing woman unless clearly indicated. Pediatric Use Safety and effectiveness in pediatric patients have not been established. Several cases of pediatric patients treated with Lamprene (clofazimine) have been reported in the literature.